Abstract
The concept of “food addiction” is gaining acceptance among the scientific community, and much is known about the influence of various components of food (e.g. high-fat, sugar, carbohydrate, salt) on behavior and physiology. Most of the studies to date have studied these consequences following relatively long-term diet manipulations and/or relatively free access to the food of interest. It is suggested that these types of studies are primarily tapping into the energy regulation and homeostatic processes that govern food intake and consumption. More recently, the overlap between the neurobiology of “reward-related” or hedonic effects of food ingestion and other reinforcers such as drugs of abuse has been highlighted, contributing to the notion that “food addiction” exists and that various components of food may be the substance of abuse. Based on preclinical animal models of drug addiction, a new direction for this field is using self-administration procedures and identifying an addiction-like behavioral phenotype in animals following various environmental, genetic, pharmacological, and neurobiological manipulations. Here we provide examples from this research area, with a focus on fat and sugar self-administration, and how the sophisticated animal models of drug addiction can be used to study the determinants and consequences of food addiction.
Keywords: Self-administration, animal models, food addiction, obesity, fat, sugar, homeostatic, neurobiology, hypothalamic, dysregulation, mesocorticolimbic, ghrelin, galanin, cocaine, antagonism, insensitivity, anorectic, d-amphetamine, relapse, appetite
Current Pharmaceutical Design
Title: Animal Models of Addiction: Fat and Sugar
Volume: 17 Issue: 12
Author(s): Drake Morgan and Glen M. Sizemore
Affiliation:
Keywords: Self-administration, animal models, food addiction, obesity, fat, sugar, homeostatic, neurobiology, hypothalamic, dysregulation, mesocorticolimbic, ghrelin, galanin, cocaine, antagonism, insensitivity, anorectic, d-amphetamine, relapse, appetite
Abstract: The concept of “food addiction” is gaining acceptance among the scientific community, and much is known about the influence of various components of food (e.g. high-fat, sugar, carbohydrate, salt) on behavior and physiology. Most of the studies to date have studied these consequences following relatively long-term diet manipulations and/or relatively free access to the food of interest. It is suggested that these types of studies are primarily tapping into the energy regulation and homeostatic processes that govern food intake and consumption. More recently, the overlap between the neurobiology of “reward-related” or hedonic effects of food ingestion and other reinforcers such as drugs of abuse has been highlighted, contributing to the notion that “food addiction” exists and that various components of food may be the substance of abuse. Based on preclinical animal models of drug addiction, a new direction for this field is using self-administration procedures and identifying an addiction-like behavioral phenotype in animals following various environmental, genetic, pharmacological, and neurobiological manipulations. Here we provide examples from this research area, with a focus on fat and sugar self-administration, and how the sophisticated animal models of drug addiction can be used to study the determinants and consequences of food addiction.
Export Options
About this article
Cite this article as:
Morgan Drake and M. Sizemore Glen, Animal Models of Addiction: Fat and Sugar, Current Pharmaceutical Design 2011; 17 (12) . https://dx.doi.org/10.2174/138161211795656747
DOI https://dx.doi.org/10.2174/138161211795656747 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anti-Cytokine Therapeutics: History and Update
Current Pharmaceutical Design Retraction Notice: Emerging Targets for COPD Therapy
Current Drug Targets - Inflammation & Allergy Acetylcholinesterase Inhibitors: Pharmacology and Toxicology
Current Neuropharmacology Editorial (Thematic Issue:Classic and New Agents to the Treatment of Affective Disorders: Some Concerns and Perspectives
Current Psychopharmacology Mechanisms of the Penetration of Blood-Borne Substances into the Brain
Current Neuropharmacology Vitiligo: Pathogenetic Hypotheses and Targets for Current Therapies
Current Drug Metabolism Targeting Signal Transduction Pathways in the Treatment of Mood Disorders: Recent Insights into the Relevance of the Wnt Pathway
CNS & Neurological Disorders - Drug Targets Dehydroepiandrosterone (DHEA): A Steroid with Multiple Effects. Is there Any Possible Option in the Treatment of Critical illness?
Current Medicinal Chemistry CD38 as a Regulator of Cellular NAD: A Novel Potential Pharmacological Target for Metabolic Conditions
Current Pharmaceutical Design Radiation-Induced Neuroinflammation and Radiation Somnolence Syndrome
CNS & Neurological Disorders - Drug Targets Multi-Target Directed Drugs as a Modern Approach for Drug Design Towards Alzheimer’s Disease: An Update
Current Medicinal Chemistry Maternal Vitamin D and its Role in Determining Fetal Origins of Mental Health
Current Pharmaceutical Design Ischemia-Reperfusion Injury of the Cochlea: Pharmacological Strategies for Cochlear Protection and Implications of Glutamate and Reactive Oxygen Species
Current Neuropharmacology Etiology of Exhibitionism in Adolescence: A Case Example of Countershame Theory
Adolescent Psychiatry Virtual Screening Against Obesity
Current Medicinal Chemistry Bedside Balance Testing in Elderly People
Current Aging Science Role of Estradiol in the Expression of Genes Involved in Serotonin Neurotransmission: Implications for Female Depression
Current Neuropharmacology The Potent Inhibitory Effect of β-D-Mannuronic Acid (M2000) as a Novel NSAID with Immunosuppressive Property on Anti-Cyclic Citrullinated Peptide Antibodies, Rheumatoid Factor and Anti-dsDNA Antibodies in Patients with Rheumatoid Arthritis
Current Drug Discovery Technologies A Healthy Gut for a Healthy Brain: Preclinical, Clinical and Regulatory Aspects
Current Neuropharmacology Pandemic of Atopic Diseases - A Lack of Microbial Exposure in Early Infancy?
Current Drug Targets - Infectious Disorders